ClinicalTrials.gg
RecruitingNCT07024173Updated Oct 2, 2026

A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer

A Phase 3 interventional study of HRS-8080 Tablet and Fulvestrant injection in Locally Advanced Breast Cancer and Metastatic Breast Cancer, sponsored by Shandong Suncadia Medicine Co., Ltd.. Recruiting at 2 sites in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Updated Oct 2, 2026Primary completion movedEligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing HRS-8080 in Breast Neoplasms — 8 open to participants now, 8 under way, 3 of them phase 3. HRS-8080 · Breast Neoplasms.

Planned enrollment
5th of 11
240 · median 180
Started
2025
with 2 others
Phase 3
3 of 11
3 open now
Registered
5th of 11
by date
Lead sponsor
11 of 11
Shandong Suncadia Medicine Co., Ltd.

Among the 11 studies testing HRS-8080 in Breast Neoplasms, this one is the 5th largest by planned enrollment, is one of 3 that started in 2025, is one of 3 in phase 3, and was the 5th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

8 of the 11 studies testing HRS-8080 in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About HRS-8080

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing HRS-8080 in Breast Neoplasms, or all of them as a file.
02

Study summary

This study is a multicenter, open-label, randomized controlled Phase 3 clinical trial. It is planned to enroll 240 female patients with locally advanced or metastatic breast cancer followed by disease progression after previous endocrine therapy.

03

Conditions studied

  • Locally Advanced Breast Cancer
  • Metastatic Breast Cancer

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 2, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women aged 18 to 75 years old (including both values).
  2. Physical Strength Status (PS) : 0 to 1 point.
  3. Patients with locally advanced or breast cancer confirmed by histology.
  4. Patients previously received 1-2 lines of endocrine therapy.
  5. Patients received no more than one in the recurrence/metastasis stage.
  6. Menstrual status (meeting any of the following conditions) : a) After bilateral ovariectomy; b) Age ≥60 years old; c) Age \< 60 years old, natural menopause ≥12 months, without receiving chemotherapy, tamoxifen (TAM), tolemiphene or ovarian castration in the past year, follicle-stimulating hormone (FSH) and estradiol are within the range; d) For patients under the age of 60 who are taking TAM or tolemiphene, the levels of FSH and estradiol are within the postmenopausal range; e) Premenopausal or perimenopausal patients received luteinizing hormone-releasing hormone (LHRH) agonist treatment during the study period, and the treatment was initiated at least 14 days before the start of the study.
  7. Patients comply with any of the following provisions of the v1.1 standard: a) There is at least one extracranial ; b) If there are no measurable lesions as stipulated above, at least one osteolytic or mixed (osteolytic and osteogenic) bone lesion that can be evaluated by computed tomography (CT) or magnetic resonance imaging (MRI) exists.
  8. Expected survival > 6 months.
  9. The functional level of the organs must meet the requirements.
  10. Female with fertility must agree to use effective measures for contraception during the study treatment period and within 7 months after the end of the study treatment period; Femalewith fertility must have a negative serum human chorionic gonadotropin (hCG) test within 7 days before enrollment in the study and must be in the non-lactation period.
  11. Voluntarily participate in this clinical trial, be willing and able to abide by the procedures related to clinical visits and research, understand the research procedures and have signed the .

Exclusion criteria

Exclusion Criteria:

  1. Patients previously received other systemic anti-tumor treatments besides chemotherapy、endocrine therapy and CDK4/6i (prior use of PI3K inhibitors or AKT inhibitors is permitted for patients with known PIK3CA mutations or PIK3CA/AKT/PTEN alterations).
  2. Nitrosorea or mitomycin was received within 6 weeks before the first study administration in this study; Have undergone major organ surgery, cytotoxic drugs, immunotherapy, , anti-tumor traditional or Chinese medicine medications within 4 weeks before the first study administration and within 4 weeks or 5 half lives (whichever is shorter) prior to the first study drug administration ; Have received endocrine therapy (referring to aromatase inhibitors [AI], etc.) and palliative radiotherapy within 2 weeks before the first study administration.
  3. the date from the first study administration to the last strong inducer administration is less than 28 days.
  4. Patients with rapid disease progression and investigators determines that endocrine therapy is not suitable or tolerant.
  5. Patients with active (uncontrolled by medical treatment or with clinical symptoms) , cancerous meningitis, spinal cord compression, or a history of primary central nervous system tumors; Patients with brain metastases who have completed treatment at least 28 days before the first study administration, have stable symptoms and do not require hormone therapy may be enrolled as appropriate, but they must be confirmed to have no cerebral hemorrhage by cranial imaging examinations such as CT, MRI or venography.
  6. A history of severe clinical cardiovascular diseases.
  7. Patients with uncontrollable tumor-related pain as judged by investigators. Patients who need pain-relieving medication must have a stable pain-relieving medication plan before entering the study.
  8. Patients who have received or systemic hormone therapy for immunosuppression within 2 weeks prior to the first medication (dose > 10 mg/d prednisone or other hormones of equivalent physiological dose), excluding nasal sprays or inhaled hormones.
  9. The damage caused by other treatments previously received by patients did not recover to grade ≤1 in the of the National Cancer Institute of the United States, Version 5.0 (NCI CTCAE v5.0) (excluding alopecia and other adverse events judged tolerable by investigators).
  10. Severe infection exists within 4 weeks before the first study administration, including but not limited to infectious complications requiring hospitalization, bacteremia, severe pneumonia, etc. There was an active infection of CTCAE grade ≥2 requiring intravenous antibiotic treatment within 2 weeks before the first study administration.
  11. Patients with arterial/venous thrombotic events that occurred within 6 months before the first study administration, such as cerebrovascular accidents, deep vein thrombosis and pulmonary embolism, etc.
  12. Patients with endometrial abnormalities, including but not limited to endometrial hyperplasia and dysfunctional uterine bleeding.
  13. Untreated active hepatitis.
  14. Patients with other malignant tumors within the past 5 years or is currently suffering from them, except for cancers with an extremely low risk of recurrence, including but not limited to radical cervical carcinoma in situ, cutaneous basal cell carcinoma and squamous cell carcinoma, and surgically treated papillary thyroid carcinoma, etc.
  15. Patients with hereditary or acquired bleeding tendency (such as hemophilia, coagulation dysfunction, etc.).
  16. Patients with a history of active diseases, immunodeficiency, or diseases and syndromes requiring systemic steroid hormone or immunosuppressive drug treatment, or having other acquired (human acquired immunodeficiency virus [] infection), congenital immunodeficiency diseases, or a history of organ transplantation (including bone marrow transplantation).
  17. There is one of the multiple factors that affect oral medication (such as inability to swallow and intestinal obstruction, etc.) or there are active gastrointestinal diseases or other diseases that may lead to factors that significantly affect drug absorption, distribution, metabolism or excretion (active, inflammatory bowel disease or chronic diarrhea, enteral syndrome or upper gastrointestinal surgery, including gastrectomy).
  18. Patients in the acute infection stage or active tuberculosis and requiring drug treatment.
  19. Patients known to be allergic to the HRS-8080 component.
  20. Pregnant and lactating women, or those planning to become pregnant during the study period.
  21. Patients with a clear history of neurological or mental disorders, or patients with a history of drug abuse or psychotropic medication abuse.
  22. Patients with other serious physical or laboratory examination abnormalities that may increase the risk of participating in the study, or interfere with the research results, as well as those deemed unsuitable for participation in the study by investigators.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    HRS-8080 Group

    Drug: HRS-8080 Tablet

  • Active comparator
    Fulvestrant Group

    Drug: Fulvestrant injection

  • Active comparator
    Exemestane in combination with Everolimus Group

    Drug: Exemestane tablets · Drug: Everolimus Tablets

  • Active comparator
    Exemestane or Anastrozole or Letrozole Group

    Drug: Exemestane tablets · Drug: Anastrozole Tablets · Drug: Letrozole Tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS) evaluated by the blinded independent central review (BICR).

    Time frame: Approximately 2 years.

Secondary outcomes

  1. Progression free survival (PFS) evaluated by investigators.

    Time frame: Approximately 2 years.

  2. Overall response rate (ORR).

    Time frame: Approximately 2 years.

  3. Clinical benefit rate (CBR).

    Time frame: Approximately 2 years.

  4. Duration of response (DOR).

    Time frame: Approximately 2 years.

  5. Overall survival (OS).

    Time frame: Approximately 3 years.

  6. Adverse events (AEs).

    Time frame: Approximately 2 years.

  7. Serious adverse events (SAEs).

    Time frame: Approximately 2 years.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Aug 2027, 25 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 25 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Aug 2027, on Oct 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2025
First posted
Jun 17, 2025
StartActual
Jul 23, 2025
Primary completionEst.
Aug 2027was Dec 2026
CompletionEst.
Dec 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2026→Aug 2027
Oct 2, 2026
Eligibility
Criteria largely rewritten (25 changes)
What changed in the criteria
Inclusion criteria
  • AddedPatients received no more than one line of chemotherapy in the recurrence/metastasis stage.
  • AddedMenstrual status (meeting any of the following conditions) : a) After bilateral ovariectomy; b) Age ≥60 years old; c) Age < 60 years old, natural menopause ≥12 months, without receiving chemotherapy, tamoxifen (TAM), tolemiphene or ovarian castration in the past year, follicle-stimulating hormone (FSH) and estradiol are within the postmenopausal range; d) For patients under the age of 60 who are taking TAM or tolemiphene, the levels of FSH and estradiol are within the postmenopausal range; e) Premenopausal or perimenopausal patients received luteinizing hormone-releasing hormone (LHRH) agonist treatment during the study period, and the treatment was initiated at least 14 days before the start of the study.
  • AddedPatients comply with any of the following provisions of the RECIST v1.1 standard: a) There is at least one extracranial measurable lesion; b) If there are no measurable lesions as stipulated above, at least one osteolytic or mixed (osteolytic and osteogenic) bone lesion that can be evaluated by computed tomography (CT) or magnetic resonance imaging (MRI) exists.
  • AddedFemale with fertility must agree to use effective contraceptive measures for contraception during the study treatment period and within 7 months after the end of the study treatment period; Femalewith fertility must have a negative serum human chorionic gonadotropin (hCG) test within 7 days before enrollment in the study and must be in the non-lactation period.
  • EditedSubjects that voluntarilyVoluntarily participate in this clinical trial, be willing and able to abide by the procedures related to clinical visits and research, understand the research procedures and have signed the informed consent.
Exclusion criteria
  • AddedPatients previously received other systemic anti-tumor treatments besides chemotherapy、endocrine therapy and CDK4/6i (prior use of PI3K inhibitors or AKT inhibitors is permitted for patients with known PIK3CA mutations or PIK3CA/AKT/PTEN alterations).
  • AddedNitrosorea or mitomycin was received within 6 weeks before the first study administration in this study; Have undergone major organ surgery, cytotoxic drugs, immunotherapy, , anti-tumor traditional or Chinese medicine medications within 4 weeks before the first study administration and within 4 weeks or 5 half lives (whichever is shorter) prior to the first study drug administration ; Have received endocrine therapy (referring to aromatase inhibitors [AI], etc.) and palliative radiotherapy within 2 weeks before the first study administration.
  • Addedthe date from the first study administration to the last CYP3A4 strong inducer administration is less than 28 days.
  • EditedPatients with rapid disease progressprogression and investigators determinedetermines that endocrine therapy is not suitable or tolerant.
  • AddedPatients with active (uncontrolled by medical treatment or with clinical symptoms) brain metastases, cancerous meningitis, spinal cord compression, or a history of primary central nervous system tumors; Patients with brain metastases who have completed treatment at least 28 days before the first study administration, have stable symptoms and do not require hormone therapy may be enrolled as appropriate, but they must be confirmed to have no cerebral hemorrhage by cranial imaging examinations such as CT, MRI or venography.
  • EditedPatients with uncontrollable tumor-related pain as judged by investigators. Patients who need pain-relieving medication must have a stable pain-relieving medication plan before entering the study.
  • RemovedSevere infection exists within 4 weeks before the first study administration.
  • AddedPatients who have received immunosuppressant or systemic hormone therapy for immunosuppression within 2 weeks prior to the first medication (dose > 10 mg/d prednisone or other corticosteroid hormones of equivalent physiological dose), excluding nasal sprays or inhaled hormones.
  • AddedThe damage caused by other treatments previously received by patients did not recover to grade ≤1 in the Common Terminology Criteria for Adverse Events of the National Cancer Institute of the United States, Version 5.0 (NCI CTCAE v5.0) (excluding alopecia and other adverse events judged tolerable by investigators).
  • AddedSevere infection exists within 4 weeks before the first study administration, including but not limited to infectious complications requiring hospitalization, bacteremia, severe pneumonia, etc. There was an active infection of CTCAE grade ≥2 requiring intravenous antibiotic treatment within 2 weeks before the first study administration.
  • AddedPatients with arterial/venous thrombotic events that occurred within 6 months before the first study administration, such as cerebrovascular accidents, deep vein thrombosis and pulmonary embolism, etc.
  • EditedPatients with clinically significant endometrial abnormalities, including but not limited to endometrial hyperplasia and dysfunctional uterine bleeding.
  • AddedPatients with other malignant tumors within the past 5 years or is currently suffering from them, except for cancers with an extremely low risk of recurrence, including but not limited to radical cervical carcinoma in situ, cutaneous basal cell carcinoma and squamous cell carcinoma, and surgically treated papillary thyroid carcinoma, etc.
  • AddedPatients with hereditary or acquired bleeding tendency (such as hemophilia, coagulation dysfunction, etc.).
  • AddedPatients with a history of active autoimmune diseases, immunodeficiency, or diseases and syndromes requiring systemic steroid hormone or immunosuppressive drug treatment, or having other acquired (human acquired immunodeficiency virus [HIV] infection), congenital immunodeficiency diseases, or a history of organ transplantation (including allogeneic bone marrow transplantation).
  • AddedThere is one of the multiple factors that affect oral medication (such as inability to swallow and intestinal obstruction, etc.) or there are active gastrointestinal diseases or other diseases that may lead to factors that significantly affect drug absorption, distribution, metabolism or excretion (active, inflammatory bowel disease or chronic diarrhea, enteral syndrome or upper gastrointestinal surgery, including gastrectomy).
  • AddedPatients in the acute infection stage or active tuberculosis and requiring drug treatment.
  • EditedPatients known to be allergic to the HRS-8080 componentscomponent.
  • AddedPatients with a clear history of neurological or mental disorders, or patients with a history of drug abuse or psychotropic medication abuse.
  • AddedPatients with other serious physical or laboratory examination abnormalities that may increase the risk of participating in the study, or interfere with the research results, as well as those deemed unsuitable for participation in the study by investigators.
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Primary completion Dec 2026→Aug 2027
    Eligibility Criteria largely rewritten (25 changes)
    What changed in the criteria
    Inclusion criteria
    • AddedPatients received no more than one line of chemotherapy in the recurrence/metastasis stage.
    • AddedMenstrual status (meeting any of the following conditions) : a) After bilateral ovariectomy; b) Age ≥60 years old; c) Age < 60 years old, natural menopause ≥12 months, without receiving chemotherapy, tamoxifen (TAM), tolemiphene or ovarian castration in the past year, follicle-stimulating hormone (FSH) and estradiol are within the postmenopausal range; d) For patients under the age of 60 who are taking TAM or tolemiphene, the levels of FSH and estradiol are within the postmenopausal range; e) Premenopausal or perimenopausal patients received luteinizing hormone-releasing hormone (LHRH) agonist treatment during the study period, and the treatment was initiated at least 14 days before the start of the study.
    • AddedPatients comply with any of the following provisions of the RECIST v1.1 standard: a) There is at least one extracranial measurable lesion; b) If there are no measurable lesions as stipulated above, at least one osteolytic or mixed (osteolytic and osteogenic) bone lesion that can be evaluated by computed tomography (CT) or magnetic resonance imaging (MRI) exists.
    • AddedFemale with fertility must agree to use effective contraceptive measures for contraception during the study treatment period and within 7 months after the end of the study treatment period; Femalewith fertility must have a negative serum human chorionic gonadotropin (hCG) test within 7 days before enrollment in the study and must be in the non-lactation period.
    • EditedSubjects that voluntarilyVoluntarily participate in this clinical trial, be willing and able to abide by the procedures related to clinical visits and research, understand the research procedures and have signed the informed consent.
    Exclusion criteria
    • AddedPatients previously received other systemic anti-tumor treatments besides chemotherapy、endocrine therapy and CDK4/6i (prior use of PI3K inhibitors or AKT inhibitors is permitted for patients with known PIK3CA mutations or PIK3CA/AKT/PTEN alterations).
    • AddedNitrosorea or mitomycin was received within 6 weeks before the first study administration in this study; Have undergone major organ surgery, cytotoxic drugs, immunotherapy, , anti-tumor traditional or Chinese medicine medications within 4 weeks before the first study administration and within 4 weeks or 5 half lives (whichever is shorter) prior to the first study drug administration ; Have received endocrine therapy (referring to aromatase inhibitors [AI], etc.) and palliative radiotherapy within 2 weeks before the first study administration.
    • Addedthe date from the first study administration to the last CYP3A4 strong inducer administration is less than 28 days.
    • EditedPatients with rapid disease progressprogression and investigators determinedetermines that endocrine therapy is not suitable or tolerant.
    • AddedPatients with active (uncontrolled by medical treatment or with clinical symptoms) brain metastases, cancerous meningitis, spinal cord compression, or a history of primary central nervous system tumors; Patients with brain metastases who have completed treatment at least 28 days before the first study administration, have stable symptoms and do not require hormone therapy may be enrolled as appropriate, but they must be confirmed to have no cerebral hemorrhage by cranial imaging examinations such as CT, MRI or venography.
    • EditedPatients with uncontrollable tumor-related pain as judged by investigators. Patients who need pain-relieving medication must have a stable pain-relieving medication plan before entering the study.
    • RemovedSevere infection exists within 4 weeks before the first study administration.
    • AddedPatients who have received immunosuppressant or systemic hormone therapy for immunosuppression within 2 weeks prior to the first medication (dose > 10 mg/d prednisone or other corticosteroid hormones of equivalent physiological dose), excluding nasal sprays or inhaled hormones.
    • AddedThe damage caused by other treatments previously received by patients did not recover to grade ≤1 in the Common Terminology Criteria for Adverse Events of the National Cancer Institute of the United States, Version 5.0 (NCI CTCAE v5.0) (excluding alopecia and other adverse events judged tolerable by investigators).
    • AddedSevere infection exists within 4 weeks before the first study administration, including but not limited to infectious complications requiring hospitalization, bacteremia, severe pneumonia, etc. There was an active infection of CTCAE grade ≥2 requiring intravenous antibiotic treatment within 2 weeks before the first study administration.
    • AddedPatients with arterial/venous thrombotic events that occurred within 6 months before the first study administration, such as cerebrovascular accidents, deep vein thrombosis and pulmonary embolism, etc.
    • EditedPatients with clinically significant endometrial abnormalities, including but not limited to endometrial hyperplasia and dysfunctional uterine bleeding.
    • AddedPatients with other malignant tumors within the past 5 years or is currently suffering from them, except for cancers with an extremely low risk of recurrence, including but not limited to radical cervical carcinoma in situ, cutaneous basal cell carcinoma and squamous cell carcinoma, and surgically treated papillary thyroid carcinoma, etc.
    • AddedPatients with hereditary or acquired bleeding tendency (such as hemophilia, coagulation dysfunction, etc.).
    • AddedPatients with a history of active autoimmune diseases, immunodeficiency, or diseases and syndromes requiring systemic steroid hormone or immunosuppressive drug treatment, or having other acquired (human acquired immunodeficiency virus [HIV] infection), congenital immunodeficiency diseases, or a history of organ transplantation (including allogeneic bone marrow transplantation).
    • AddedThere is one of the multiple factors that affect oral medication (such as inability to swallow and intestinal obstruction, etc.) or there are active gastrointestinal diseases or other diseases that may lead to factors that significantly affect drug absorption, distribution, metabolism or excretion (active, inflammatory bowel disease or chronic diarrhea, enteral syndrome or upper gastrointestinal surgery, including gastrectomy).
    • AddedPatients in the acute infection stage or active tuberculosis and requiring drug treatment.
    • EditedPatients known to be allergic to the HRS-8080 componentscomponent.
    • AddedPatients with a clear history of neurological or mental disorders, or patients with a history of drug abuse or psychotropic medication abuse.
    • AddedPatients with other serious physical or laboratory examination abnormalities that may increase the risk of participating in the study, or interfere with the research results, as well as those deemed unsuitable for participation in the study by investigators.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07024173
Responsible party
Sponsor
First posted
Jun 17, 2025
Start date
Jul 23, 2025
Primary completion
Aug 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Min Li
Contact
min.li.ml150@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-8080

Start the discussion